Linifanib is a small molecule inhibitor of vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) families of receptor tyrosine kinases used for oral treatment of multiple advanced cancers22, including breast cancer23, colorectal cancer (CRC)24, non-small cell lung cancer (NSCLC)25, renal cell carcinoma (RCC)26 and hepatocellular carcinoma (HCC)27,28. This evidence concerns the gene VEGFA and colorectal cancer.